Details of Disease

General Information of Disease (ID: DIS18R3K)

• Disease Name: Metastatic colorectal cancer
• Disease Class: 2B91: Colorectal cancer
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DIS18R3K: Metastatic colorectal cancer
• ICD Code:
  ICD-11: ICD-11: 2B91
  ICD-10: ICD-10: C19
  Expand ICD-9: 153154

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 4 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aflibercept	DMT3D5I	Approved	NA	[1]
Bevacizumab	DMSD1UN	Approved	Monoclonal antibody	[1]
Regorafenib	DMHSY1I	Approved	Small molecular drug	[2]
Retifanlimab	DMRKTCP	Approved	Antibody	[3]

This Disease is Treated as An Indication in 16 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CPI-613	DM5XUQL	Phase 3	Small molecular drug	[4]
SYM-004	DMOVEDH	Phase 3	Antibody	[4]
AlloStim	DMC9T4O	Phase 2/3	NA	[5]
CV301	DM4KY08	Phase 2	Vaccine	[6]
Efatutazone	DM0M71T	Phase 2	Small molecular drug	[7]
LOR-2040	DMX2TEM	Phase 2	NA	[8]
MEGF0444A	DM2C1YN	Phase 2	NA	[9]
PEG-SN38	DMX9ZM4	Phase 2	Small molecular drug	[10]
RG7221	DM8J9DC	Phase 2	NA	[11]
Saracatinib	DMBLHGP	Phase 2	Small molecular drug	[12]
Sibrotuzumab	DMT4UC1	Phase 2	Antibody	[13]
AB928	DMDOXMN	Phase 1/2	NA	[14]
Encapsulated cell therapy	DMC0A4W	Phase 1/2	NA	[15]
MGD007	DMAHWLR	Phase 1/2	Monoclonal antibody	[11]
BNC-101	DMSBM6A	Phase 1	Antibody	[16]
Navicixizumab	DMZ2G69	Phase 1	NA	[4]

This Disease is Treated as An Indication in 2 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
RG7160	DM5KJGB	Discontinued in Phase 2	NA	[17]
Nimesulide	DMR1NMD	Terminated	Small molecular drug	[18]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5891).
• [3] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] ClinicalTrials.gov (NCT03547999) A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC. U.S. National Institutes of Health.
• [7] ClinicalTrials.gov (NCT02152137) Efatutazone With Paclitaxel Versus Paclitaxel Alone in Treating Patients With Advanced Anaplastic Thyroid Cancer. U.S. National Institutes of Health.
• [8] ClinicalTrials.gov (NCT00087165) GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer. U.S. National Institutes of Health.
• [9] ClinicalTrials.gov (NCT00909740) A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [10] ClinicalTrials.gov (NCT01036113) A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer. U.S. National Institutes of Health.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] Phase II Study of Saracatinib (AZD0530) in Patients With Previously Treated Metastatic Colorectal Cancer. Invest New Drugs. 2015 Aug;33(4):977-84.
• [13] ClinicalTrials.gov (NCT02198274) Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer. U.S. National Institutes of Health.
• [14] ClinicalTrials.gov (NCT04660812) An Open Label Study Evaluating the Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer.. U.S. National Institutes of Health.
• [15] VC-01's Path to the Clinic. Viacyte. 2015.
• [16] ClinicalTrials.gov (NCT02726334) A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.. U.S. National Institutes of Health.
• [17] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029052)
• [18] Clinical pipeline report, company report or official report of Genentech (2011).
• [19] ClinicalTrials.gov (NCT00130728) A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
• [20] Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.